ASH 2022 | Current status & progress in CAR-T therapy for hematological malignancies
Michael Bishop, MD, University of Chicago, Chicago, IL, shares insights into the latest developments in CAR-T research for hematological malignancies. Prof. Bishop highlights the research on enhancing CAR-T function and overcoming mechanisms of resistance to CAR-T therapy, with the end goal of improving the durability of responses. Following this, Prof. Bishop discusses current Phase II and Phase III studies using CAR-T as third, second, and front-line therapy in patients with multiple myeloma. Finally, Prof. Bishop comments on trials evaluating CAR-T therapies in other hematological malignancies including acute myeloid leukemia (AML), Hodgkin lymphoma (HL), and T-cell lymphoma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bristol Myers Squibb: Honoraria, Other: Travel support, Speakers Bureau; Novartis: Consultancy, Honoraria, Other: Travel support , Research Funding; CRISPR Therapeutics: Consultancy, Research Funding; Agios: Consultancy, Honoraria, Other: Travel support, Speakers Bureau; Iovance: Consultancy; Bluebird Bio: Consultancy; WindMIL Therapeutics: Consultancy; Arcellx: Consultancy, Research Funding; Autolus: Consultancy, Research Funding; Immatics: Research Funding; Triumvira: Research Funding; Tmunity: Research Funding; Chimeric Therapeutics: Consultancy; Sanofi: Honoraria, Speakers Bureau; Sana Biotechnology: Consultancy; Servier: Speakers Bureau; ADC Therapeutics: Speakers Bureau; Celgene: Honoraria; Incyte: Honoraria, Other: Travel support , Speakers Bureau; Kite, a Gilead Company: Consultancy, Honoraria, Other: Travel support, Research Funding, Speakers Bureau.
